Note From the Authors

The IVC book does not constitute medical advice.  Additionally, the authors have no connections with the IVC industry (if there is such a thing for such a relatively cheap, non-proprietary, and easily-done treatment).

Besides IVC, there is no other single treatment that helps all of the 16 QOL (quality of life) factors (“the sweet 16”) while also addressing all off cancer’s “dirty dozen” strategies to sap away life.  It therefore seemed remarkable to us that until now nothing like this book has existed.  This work is the result of investigating cancer treatments over the last 10+ years, and deep investigation of over 100’s of peer-reviewed journals on the subject.  You will find it to be a short yet comprehensive easy-to-read handbook, designed as an easy reference as well as an engaging narrative from cover to cover, justified with comprehensive peer-reviewed citations throughout.

Specific efforts have been made to make this different than most medical books aimed primarily at a lay audience, but also suitable for physicians.  Specifically this book is as accurate as possible while being approachable for patients, practitioner, and patient-care advocates.  It contains:

No dumbing-down errors.   Health books written in part for lay persons often simplify in a way that misrepresents treatment efficacy, instead of accurately describing in terms of probability. Peer-reviewed journal articles don’t err in this way. Neither does this book.

No hyperbole.  We respect the reader’s ability to think for themselves when given the data straight in an easy-to-read way.

Patient Empowerment.  Our goal is to help the patient be prudent, “fight” on their own terms, know what they can personally do on their own to improve their chance for recovery, and get the best care to maximize their treatment efficacy.

In addition to helping improve IVC administration, we hope that this will influence some political will for the NIH to fund well administered highly-transparent Randomized Controlled Trials of hundreds of typical (not just late-stage) human cancer patients using proper protocols recommended herein to better identify key parameters and to research new, improved, and refined IVC-related protocols (see end of Chapter 6, Chapter 8).

In the meantime we hope to spread the immutable fact that IVC and similarly cancer-selective IV therapies are unsurpassed in the number of ways it can help patients as they beat cancer.  We hope this extremely neglected treatment will find its rightful place within conventional oncology, instead of relegated only to those few doctors who’ve explored beyond their canon despite the overwhelming amount of paperwork already keeping them from their passion to help others.

– The Authors